ArticleVaccine2015
Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine.
Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 62 citations in OpenAlex.
- Glanders: Past, Present and Future of a Neglected Zoonosis as a Threat in Veterinary and Human Health.Veterinary medicine and science · 2026Review
- Glanders: An ancient and emergent disease with no vaccine or treatment on site.PLoS neglected tropical diseases · 2025Review
- Melioidosis vaccines: recent advances and future directions.Frontiers in immunology · 2025Review
- Review
- Efficacy of EHEC gold nanoparticle vaccines evaluated with the Shiga toxin-producingMicrobiology spectrum · 2024Article
- Knowledge, awareness and perception about equine glanders among veterinarians and medical professionals in India.Frontiers in veterinary science · 2024Article
- NHP BurkPx: A multiplex serodiagnostic bead assay to monitor Burkholderia pseudomallei exposures in non-human primates.PLoS neglected tropical diseases · 2023Article
- Nano toolbox in immune modulation and nanovaccines.Trends in biotechnology · 2022Review
- Recent advances on smart glycoconjugate vaccines in infections and cancer.The FEBS journal · 2022Review
- Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases.Vaccines · 2022Review
- Preparation and immunological properties of a nanovaccine againstIranian journal of basic medical sciences · 2021Article
- Current Advances inCells · 2020Review
- Article
- Combating the great mimicker: latest progress in the development ofExpert review of vaccines · 2020Review
- Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases.Expert review of vaccines · 2020Review
- Development of a Gold Nanoparticle Vaccine against Enterohemorrhagic Escherichia coli O157:H7.mBio · 2019Article
- Designing inorganic nanomaterials for vaccines and immunotherapies.Nano today · 2019Article
- Impact of Binge Alcohol Intoxication on the Humoral Immune Response duringMicroorganisms · 2019Article
- Novel multi-component vaccine approaches for Burkholderia pseudomallei.Clinical and experimental immunology · 2019Review
- The autotransporter protein BatA is a protective antigen against lethal aerosol infection withVaccine: X · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The Gram-negative Burkholderia mallei is a zoonotic pathogen and the causative agent of glanders disease. Because the bacteria maintain the potential to be used as a biothreat agent, vaccine strategies are required for human glanders prophylaxis. A rhesus macaque (Macaca mulatta) model of pneumonic (inhalational) glanders was established and the protective properties of a nanoparticle glycoconjugate vaccine composed of Burkholderia thailandensis LPS conjugated to FliC was evaluated. An aerosol challenge dose of ∼1×10(4) CFU B. mallei produced mortality in 50% of naïve animals (n=2/4), 2-3 days post-exposure. Although survival benefit was not observed by vaccination with a glycoconjugate glanders vaccine (p=0.42), serum LPS-specific IgG titers were significantly higher on day 80 in 3 vaccinated animals who survived compared with 3 vaccinated animals who died. Furthermore, B. mallei was isolated from multiple organs of both non-vaccinated survivors, but not from any organs of 3 vaccinated survivors at 30 days post-challenge. Taken together, this is the first time a candidate vaccine has been evaluated in a non-human primate aerosol model of glanders and represents the initial step for consideration in pre-clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.